Purple biotech announces exercise of warrants for $2 million gross proceeds

Rehovot, israel, july 01, 2024 (globe newswire) -- purple biotech ltd. (“purple biotech” or “the company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 american depositary shares (adss), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ads, originally issued by purple biotech in october 2023, june 2020, january 2019 and june 2018, at a reduced exercise price of $0.36 per ads. the issuance and/or resale of the adss issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on form f-3 (file nos. 333-268710, 333-235327 and 333-215037). the offering is expected to close on or about july 2, 2024, subject to satisfaction of customary closing conditions.
PPBT Ratings Summary
PPBT Quant Ranking